The SH-1 Molecule by Dr. Melvin Sewell

June 2026 in “ Zenodo (CERN European Organization for Nuclear Research) ”

Melvin Sewell

SH-1 molecule androgen receptor antagonist androgenetic alopecia hair follicle miniaturization endocrine balance AGA

Preprint — not peer reviewed. This was posted to a preprint server or data repository. It has not been through a journal's review process, and its findings may change or not hold up.

Studysummary This source describes SH‑1 as a next-generation androgen receptor antagonist designed for localized treatment of androgenetic alopecia, aiming to reverse follicular miniaturization while maintaining endocrine balance. Unlike traditional therapies, SH‑1 offers tissue-specific action, avoiding systemic effects.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer ·

View this study on zenodo.org →

Discuss this study in the Community →

Similar Research

5 / 1000+ results

research The SH-1 Molecule By Dr. Melvin Sewell

June 2026 in “HAL (Le Centre pour la Communication Scientifique Directe)”

This article presents the SH-1 molecule as a novel AR antagonist for androgenetic alopecia treatment, highlighting its tissue-specific action and potential for commercialization, but provides no new clinical results.

research 52243 AH-001: An Emerging Androgen Receptor Degrader Showing Therapeutic Potential in Addressing Androgenetic Alopecia (AGA)

September 2024 in “Journal of the American Academy of Dermatology”

In this study, a novel compound named AH-001 demonstrated effective androgen receptor protein degradation, reducing hair loss progression in a mouse model of androgenetic alopecia, with minimal systemic exposure and side effects, suggesting potential for safer treatment.

research Mechanotransduction in Androgenetic Alopecia: An In Silico Repositioning Study of PIEZO1 + MLCK Axis Using Cofolding and Pilosebaceous Single-Cell Atlas Constraints

January 2026 in “Open MIND”

This study identified candidate compounds from a natural-product library that may interact with the PIEZO1 and MLCK pathways, potentially countering a non-androgen cause of hair follicle miniaturization, all based on computer simulations; experimental validation is necessary.

research Caffeic acid N-[3,5-bis(trifluoromethyl)phenyl] amide as a non-steroidal inhibitor for steroid 5α-reductase type 1 using a human keratinocyte cell-based assay and molecular dynamics

December 2022 in “Scientific Reports”

This study found that caffeic acid amide derivative, compound 4, effectively inhibited steroid 5α-reductase type 1 in vitro, suggesting potential for development as a treatment for androgenic alopecia.

Discovery of (2S)-N-(6-Cyano-5-(Trifluoromethyl)Pyridin-3-Yl)-3-(6-(4-Cyanophenyl)-3,6-Diazabicyclo[3.1.1]Heptan-3-Yl)-2-Hydroxy-2-Methylpropanamide as a Highly Potent and Selective Topical Androgen Receptor Antagonist for Androgenetic Alopecia Treatment

research Discovery of (2S)-N-(6-Cyano-5-(trifluoromethyl)pyridin-3-yl)-3-(6-(4-cyanophenyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)-2-hydroxy-2-methylpropanamide as a Highly Potent and Selective Topical Androgen Receptor Antagonist for Androgenetic Alopecia Treatment

December 2023 in “Journal of Medicinal Chemistry”

In this study, researchers identified compound 30a as a promising topical androgen receptor antagonist that promoted hair growth in mouse models of androgenetic alopecia without noticeable toxicity, suggesting its potential for treating this hair loss condition.